Search

Corvus Pharmaceuticals Inc

Open

14.22 -0.07

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

13.87

Max

14.72

Belangrijke statistieken

By Trading Economics

Inkomsten

-4.3M

-18M

EPS

-0.19

Werknemers

37

EBITDA

-5.3M

-17M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+106.73% upside

Dividenden

By Acuity

Volgende Winsten

3 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

57M

1.2B

Vorige openingsprijs

14.29

Vorige sluitingsprijs

14.22

Corvus Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

1 sep 2026, 23:56 UTC

Correlated Moves

Shares declined in after-market trading amid rising oil prices.

1 sep 2026, 23:56 UTC

Cricut Inc shares are lower in after-market trading amid broader market pressures and declining oil prices, reflecting heightened inflation concerns.

1 sep 2026, 23:56 UTC

Fidelity National Information Services remains near unchanged in after-market trading, with no specific news identified and a position below its 20-day moving average.

1 sep 2026, 23:56 UTC

monday.com Ltd. shares traded roughly flat in after-market hours. The stock remains above its 20-day moving average and near the upper end of its one-month range.

1 sep 2026, 23:56 UTC

Cognizant Technology Solutions shares are lower in after-market trading, amid broader market pressure from rising oil prices and geopolitical tensions.

1 sep 2026, 23:56 UTC

News

Wix.com Ltd faces a securities class action lawsuit over alleged false statements about its AI products, leading shares to trade lower in after-market hours.

1 sep 2026, 23:56 UTC

Becton Dickinson and Co shares rose in after-market trading, reflecting a position above its 20-day moving average and near the top of its one-month range.

1 sep 2026, 23:56 UTC

United States Copper Index Fund is higher in after-market hours, maintaining resilience amid broader market declines driven by rising oil prices and inflation concerns.

1 sep 2026, 23:56 UTC

Arbor Realty Trust Inc. shares rose in after-market trading, despite broader market pressures and rising oil prices raising inflation concerns among investors.

1 sep 2026, 23:56 UTC

Travelers Companies Inc shares are lower in after-market hours, with no specific news identified. Rising oil prices contribute to broader inflation concerns affecting equities.

1 sep 2026, 23:56 UTC

ON Semiconductor shares are lower in after-market hours, reflecting broader market pressure amid rising oil prices and inflation concerns.

1 sep 2026, 23:56 UTC

Ecolab Inc shares are higher in after-market hours amid rising oil prices and geopolitical tensions, despite broader market pressures from inflation concerns.

1 sep 2026, 23:56 UTC

Merit Medical Systems Inc shares are higher in after-market hours, reflecting strong performance despite broader market pressures from rising oil prices and inflation concerns.

1 sep 2026, 23:56 UTC

Martin Marietta Materials Inc. shares are higher in after-market trading, recovering from earlier declines despite ongoing pressures from rising oil prices and inflation concerns.

1 sep 2026, 23:56 UTC

News

AbbVie Inc. has filed for a new Skyrizi regimen to treat Crohn's disease. Shares are lower in after-market hours amid broader market pressure from rising oil prices.

1 sep 2026, 23:56 UTC

Geron Corp shares are higher in after-market trading, reflecting a positive move since Tuesday's close amid broader market fluctuations. No specific news was identified.

1 sep 2026, 23:56 UTC

Check Point Software Technologies shares are lower in after-market trading, following earlier volatility and broader market pressure from rising oil prices.

1 sep 2026, 23:52 UTC

Clean Harbors Inc shares are lower in after-market trading, declining after a near-flat position. No specific news was identified to explain the movement.

1 sep 2026, 23:52 UTC

Huntington Bancshares Inc shares are higher in after-market hours, recovering from a session low despite trading below its 20-day moving average.

1 sep 2026, 23:51 UTC

Bank of Hawaii Corp shares are higher in after-market trading, recovering from an earlier dip. The stock remains below its 20-day moving average.

1 sep 2026, 23:51 UTC

ETF Constituents
Macro News

iShares MSCI Germany ETF declines in after-market hours amid global equity market pressure from macroeconomic concerns and rising crude oil prices.

1 sep 2026, 23:51 UTC

News

Telephone and Data Systems withdraws Array Digital Infrastructure acquisition proposal and resumes share repurchase program. Shares rise in after-market trading.

1 sep 2026, 23:51 UTC

Correlated Moves

Shares of Comfort Systems USA Inc. declined in after-market trading, influenced by broader market sentiment and rising oil prices amid geopolitical tensions.

1 sep 2026, 23:51 UTC

News
Correlated Moves

EOG Resources shares are higher after the company announced participation in the Barclays Energy-Power Conference, with oil prices surpassing $90 per barrel.

1 sep 2026, 23:51 UTC

Unity Software Inc. shares are trading higher in after-market hours, breaking from a recent trend of consecutive daily gains.

1 sep 2026, 23:51 UTC

Correlated Moves
Social Media

ConocoPhillips shares are lower in after-market hours amid broader energy sector scrutiny, despite rising crude oil prices above $90 per barrel.

1 sep 2026, 23:51 UTC

Verizon Communications Inc shares are lower in after-market hours, with no specific news identified to explain the decline. Oil price increases raise inflation concerns.

1 sep 2026, 23:51 UTC

European equities decline as oil prices surge and geopolitical tensions rise, fueling inflation fears and bond market sell-off ahead of potential ECB interest rate hikes.

1 sep 2026, 23:51 UTC

Global equity markets decline as oil prices surge over 5% amid U.S.-Iran tensions, while weak U.S. job openings and Eurozone inflation rise raise concerns over economic stability.

1 sep 2026, 23:51 UTC

U.S. equity indices decline as rising oil prices and bond yields heighten inflation fears amid geopolitical tensions, with investors bracing for potential stagflation risks.

Peer Vergelijking

Prijswijziging

Corvus Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

106.73% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 29.5 USD  106.73%

Hoogste 33 USD

Laagste 27 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corvus Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat